CN117119907A - 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法 - Google Patents

使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法 Download PDF

Info

Publication number
CN117119907A
CN117119907A CN202280027370.7A CN202280027370A CN117119907A CN 117119907 A CN117119907 A CN 117119907A CN 202280027370 A CN202280027370 A CN 202280027370A CN 117119907 A CN117119907 A CN 117119907A
Authority
CN
China
Prior art keywords
vitamin
subject
inositol
sorbitol
erythritol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280027370.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·周
S·K·多格拉
A·达迪尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA filed Critical Societe des Produits Nestle SA
Publication of CN117119907A publication Critical patent/CN117119907A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280027370.7A 2021-05-06 2022-05-04 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法 Pending CN117119907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185097P 2021-05-06 2021-05-06
US63/185,097 2021-05-06
PCT/EP2022/061949 WO2022233922A1 (en) 2021-05-06 2022-05-04 Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii

Publications (1)

Publication Number Publication Date
CN117119907A true CN117119907A (zh) 2023-11-24

Family

ID=81941092

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280027370.7A Pending CN117119907A (zh) 2021-05-06 2022-05-04 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法

Country Status (5)

Country Link
US (1) US20240226030A1 (enExample)
EP (1) EP4333644A1 (enExample)
JP (1) JP2024518270A (enExample)
CN (1) CN117119907A (enExample)
WO (1) WO2022233922A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202316101D0 (en) * 2023-10-20 2023-12-06 Tate & Lyle Solutions Usa Llc Compositions and uses
WO2025083419A1 (en) * 2023-10-20 2025-04-24 Tate & Lyle Solutions Usa Llc Allulose or erythritol for use in improving gut microbiota population and medical treatment

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1902189A (zh) * 2003-11-04 2007-01-24 明治乳业株式会社 来自于植物的β3肾上腺素能受体激动性物质及其利用
CN101156867A (zh) * 2007-10-19 2008-04-09 北京协和建昊医药技术开发有限责任公司 茶多酚膜剂及其制备方法
US20110189318A1 (en) * 2010-01-29 2011-08-04 Misato Sugahara Methods for enhancing the expression of intracellular redox-associated factors
JP2012065607A (ja) * 2010-09-24 2012-04-05 Hirotaro Matsui サプリメント
US20130028921A1 (en) * 2010-03-31 2013-01-31 Amorepacific Corporation Composition comprising coumestrol or a bean extract containing coumestrol
CN103372024A (zh) * 2012-04-25 2013-10-30 上野制药株式会社 晚期糖化终产物生成抑制剂
CN106794206A (zh) * 2014-08-08 2017-05-31 雀巢产品技术援助有限公司 肌醇和一种或多种益生菌以及它们的用途
CN107252112A (zh) * 2017-06-08 2017-10-17 杭州茗朗生物科技有限公司 一种含egcg的片剂
CN107802576A (zh) * 2016-09-07 2018-03-16 酷美生物科技（上海）有限公司 一种天然动植物细胞补充剂及其制备方法
CN108367030A (zh) * 2015-10-28 2018-08-03 麦太宝根有限公司 普氏粪杆菌和惰性脱硫弧菌用于治疗或预防糖尿病和肠病
CN110973630A (zh) * 2019-12-20 2020-04-10 美益添生物医药(武汉)有限公司 一种抗肠道衰老的组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007051132A (ja) * 2005-07-19 2007-03-01 Hokkaido Sugar Co Ltd イノシトールを成分とする食用組成物または医薬組成物
WO2010083227A1 (en) * 2009-01-14 2010-07-22 Nutrafood Nutrients, Inc. Consumable dissolving film comprising active ingredients derived from bacteria and fungi
US20140023701A1 (en) * 2011-04-07 2014-01-23 Nugevity Llc Method and Composition for Ameliorating the Effects tor a Subject Exposed to Radiation or Other Sources of Oxidative Stress
US20150209383A1 (en) * 2011-11-04 2015-07-30 General Mills, Inc. Methods and compositions for modulating gastrointestinal bacteria to promote health
MX2015011700A (es) * 2013-03-05 2016-07-20 Univ Groningen Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
US11484569B2 (en) * 2017-07-13 2022-11-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria
US11898184B2 (en) * 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
CN108309960A (zh) * 2018-04-24 2018-07-24 温州医科大学附属第医院 肌醇在制备抗炎药物中的应用
FR3099053B1 (fr) * 2019-07-24 2023-01-20 Inst Nat De La Rech Agronomique Inra Souches bacteriennes pour le traitement et la prevention d’une inflammation gastro-intestinale
CN112402459B (zh) * 2020-10-27 2023-01-31 江南大学 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用
CN112625964B (zh) * 2020-12-29 2022-08-02 江南大学 一株鼠李糖乳杆菌在预防和缓解溃疡性结肠炎中的应用

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1902189A (zh) * 2003-11-04 2007-01-24 明治乳业株式会社 来自于植物的β3肾上腺素能受体激动性物质及其利用
CN101156867A (zh) * 2007-10-19 2008-04-09 北京协和建昊医药技术开发有限责任公司 茶多酚膜剂及其制备方法
US20110189318A1 (en) * 2010-01-29 2011-08-04 Misato Sugahara Methods for enhancing the expression of intracellular redox-associated factors
US20130028921A1 (en) * 2010-03-31 2013-01-31 Amorepacific Corporation Composition comprising coumestrol or a bean extract containing coumestrol
JP2012065607A (ja) * 2010-09-24 2012-04-05 Hirotaro Matsui サプリメント
CN103372024A (zh) * 2012-04-25 2013-10-30 上野制药株式会社 晚期糖化终产物生成抑制剂
CN106794206A (zh) * 2014-08-08 2017-05-31 雀巢产品技术援助有限公司 肌醇和一种或多种益生菌以及它们的用途
CN108367030A (zh) * 2015-10-28 2018-08-03 麦太宝根有限公司 普氏粪杆菌和惰性脱硫弧菌用于治疗或预防糖尿病和肠病
CN107802576A (zh) * 2016-09-07 2018-03-16 酷美生物科技（上海）有限公司 一种天然动植物细胞补充剂及其制备方法
CN107252112A (zh) * 2017-06-08 2017-10-17 杭州茗朗生物科技有限公司 一种含egcg的片剂
CN110973630A (zh) * 2019-12-20 2020-04-10 美益添生物医药(武汉)有限公司 一种抗肠道衰老的组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUAIXIU WEN, BOWEN TANG, ALAN J. STEWART, YANDUO TAO, YUN SHAO, YULEI CUI, HUILAN YUE, JINJIN PEI, ZENGGEN LIU, LIJUAN MEI, RUITAO: "Erythritol Attenuates Postprandial Blood Glucose by Inhibiting α‑Glucosidase", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 66, 31 December 2018 (2018-12-31), pages 1401 *

Also Published As

Publication number Publication date
US20240226030A1 (en) 2024-07-11
JP2024518270A (ja) 2024-05-01
EP4333644A1 (en) 2024-03-13
WO2022233922A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US11701397B2 (en) Use of L. reuteri for recovery of microbiota dysbiosis in early life
Sen Role of probiotics in health and disease–A review
CN109562117A (zh) 具有2FL和LNnT的营养组合物，用于通过作用于肠道微生物群生态失调来预防和/或治疗非轮状病毒腹泻
CA2953030A1 (en) Myo-inositol and one or more probiotic and use thereof
CN116981468A (zh) 益生菌组合物以及使用其促进儿童生长和社交功能的方法
US20240226030A1 (en) Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
Karatas et al. The low maternal consumption of homemade fermented foods in pregnancy is an additional risk factor for food protein-induced allergic proctocolitis: a case-control study
Smilowitz et al. Tolerability and safety of the intake of bovine milk oligosaccharides extracted from cheese whey in healthy human adults
WO2026082208A1 (zh) 活性叶酸类物质有助于调节母子肠道菌群的用途
KR20220097322A (ko) 케스토스를 이용한 프로피온산 증진 용도
JP2022535718A (ja) 非セリアック小麦及び／又はグルテン過敏症を患っている患者の症状の処置において使用するためのヒトミルクオリゴ糖
US20240293485A1 (en) Compositions and methods using a combination of at least one fiber and at least one probiotic to improve microbiome resilience
US20250228809A1 (en) Compositions for use
US20240282458A1 (en) Methods of determining and using a microbiome resilience index
KAYA et al. Different approaches to nutrition in children with autism spectrum disorder
CN120091764A (zh) 使用至少一种纤维和至少一种益生菌的组合来改善和/或维持最佳胆固醇水平的组合物和方法
WO2025190541A1 (en) Promoting butyrate-producing bacteria in the gut microbiome
CN120187441A (zh) 使用至少一种纤维和至少一种益生菌的组合来调节肠道细菌与胆固醇的关联的组合物和方法
CN120917147A (zh) 供使用的组合物
US20250228810A1 (en) Compositions for use
HK40115894B (zh) 母乳低聚糖改善母婴肠道菌群的用途
AU2024263731A1 (en) Compositions comprising human milk oligosaccharides for use in a subject to support brain development and/or cognitive development
CN118613177A (zh) 通过促进肠道微生物群中的卵形布劳特氏菌来降低痢疾发生率的组合物和方法
HK1238165A1 (en) Use of l. reuteri for recovery of microbiota dysbiosis in early life

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination